SG11201805468RA - Pharmaceutical composition for preventing or treating regulatory t cell-mediated diseases - Google Patents

Pharmaceutical composition for preventing or treating regulatory t cell-mediated diseases

Info

Publication number
SG11201805468RA
SG11201805468RA SG11201805468RA SG11201805468RA SG11201805468RA SG 11201805468R A SG11201805468R A SG 11201805468RA SG 11201805468R A SG11201805468R A SG 11201805468RA SG 11201805468R A SG11201805468R A SG 11201805468RA SG 11201805468R A SG11201805468R A SG 11201805468RA
Authority
SG
Singapore
Prior art keywords
cell
regulatory
icosl
cells
preventing
Prior art date
Application number
SG11201805468RA
Inventor
Sun Uk Song
Tac Ghee Yi
Hyun Joo Lee
Original Assignee
Scm Lifescience Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scm Lifescience Co Ltd filed Critical Scm Lifescience Co Ltd
Publication of SG11201805468RA publication Critical patent/SG11201805468RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2301—Interleukin-1 (IL-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/90—Polysaccharides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1352—Mesenchymal stem cells
    • C12N2502/1358—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to a composition and a method for inducing CD4+ T cells to differentiate into regulatory T cells and proliferate through an induced T cell co-stimulator ligand (ICOSL) or an ICOSL- overexpressing mesenchymal stem cell and for preventing or treating regulatory T cell-mediated 5 diseases. The induced T cell co-stimulator ligand (ICOSL) or ICOSL-overexpressing mesenchymal stem cell according to the present invention effectively suppresses the proliferation of PBMCs, induces the expression of an ICOS in regulatory T cells, thereby inducing the differentiation and proliferation of the regulatory T cells through a PI3K-Akt mechanism, and thus can effectively prevent, treat, or enhance 10 regulatory T cell-mediated diseases.
SG11201805468RA 2016-02-26 2017-02-24 Pharmaceutical composition for preventing or treating regulatory t cell-mediated diseases SG11201805468RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160023551 2016-02-26
PCT/KR2017/002096 WO2017146538A1 (en) 2016-02-26 2017-02-24 Pharmaceutical composition for preventing or treating regulatory t cell-mediated diseases

Publications (1)

Publication Number Publication Date
SG11201805468RA true SG11201805468RA (en) 2018-07-30

Family

ID=59685776

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201805468RA SG11201805468RA (en) 2016-02-26 2017-02-24 Pharmaceutical composition for preventing or treating regulatory t cell-mediated diseases
SG10201912046VA SG10201912046VA (en) 2016-02-26 2017-02-24 Pharmaceutical composition for preventing or treating regulatory t cell-mediated diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201912046VA SG10201912046VA (en) 2016-02-26 2017-02-24 Pharmaceutical composition for preventing or treating regulatory t cell-mediated diseases

Country Status (9)

Country Link
US (1) US11096967B2 (en)
EP (1) EP3388514B1 (en)
JP (1) JP6580791B2 (en)
KR (1) KR102025417B1 (en)
CN (1) CN108699524B (en)
AU (1) AU2017224499B2 (en)
RU (1) RU2727900C2 (en)
SG (2) SG11201805468RA (en)
WO (1) WO2017146538A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11058729B2 (en) * 2018-01-25 2021-07-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Exosomes and miRNA to treat glaucoma
CN111454888A (en) * 2019-01-18 2020-07-28 天津市第一中心医院 Stem cell processing method, cells obtained by using method and application
KR102268242B1 (en) * 2020-01-06 2021-06-23 에스씨엠생명과학 주식회사 Composition for enhancing activity of stem cells
CN111481573A (en) * 2020-03-26 2020-08-04 卡替（上海）生物技术股份有限公司 Application of dental pulp mesenchymal stem cells in preparation of medicine for treating Crohn's disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2290052T3 (en) * 1999-09-21 2008-02-16 Genetics Institute, Llc GL50 MOLECULES AND USES FOR THE SAME.
WO2005103086A1 (en) * 2004-04-23 2005-11-03 Bundesrepublik Deutschland letztvertreten durch das Robert-Koch-Institut vertreten durch seinen Präsidenten Method for the treatment of t cell mediated conditions by depletion of icos-positive cells in vivo
JPWO2006003999A1 (en) * 2004-07-05 2008-07-31 財団法人化学及血清療法研究所 Human anti-human B7RP-1 antibody and antibody fragment thereof
ZA200805079B (en) * 2005-12-08 2009-08-26 Univ Louisville Res Found Immunostimulatory compositions and methods
AU2008313693B2 (en) * 2007-10-17 2014-04-24 Txcell Tr1 cells, mesenchymal stem cells and uses thereof
SG190627A1 (en) * 2008-03-13 2013-06-28 Biotest Ag Agent for treating disease
CN104826106B (en) * 2009-09-30 2019-01-11 斯隆凯特林防癌纪念中心 Combination immunotherapy for treating cancer
ES2724451T3 (en) * 2010-02-04 2019-09-11 Univ Pennsylvania ICOS fundamentally regulates the expansion and function of inflammatory human Th17 lymphocytes
JP5900865B2 (en) 2012-04-26 2016-04-06 国立大学法人京都大学 T cell differentiation induction method, T cell production method, T cell, pharmaceutical composition, and screening method
ES2434853B1 (en) * 2012-06-12 2014-09-30 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii Molecular marker of therapeutic potency of human mesenchymal stem cells and their uses
WO2015088414A1 (en) * 2013-12-13 2015-06-18 Isletone Ab Immunomodulatory compositions
DK3029137T3 (en) * 2014-12-06 2019-04-08 Gemoab Monoclonals Gmbh GENETICALLY MODIFIED PLURI OR MULTIPOTENT STEM CELLS AND USE THEREOF

Also Published As

Publication number Publication date
JP2019501183A (en) 2019-01-17
SG10201912046VA (en) 2020-02-27
WO2017146538A1 (en) 2017-08-31
JP6580791B2 (en) 2019-09-25
KR20170101147A (en) 2017-09-05
RU2018124640A3 (en) 2020-01-09
AU2017224499A1 (en) 2018-07-26
RU2018124640A (en) 2020-01-09
CN108699524A (en) 2018-10-23
EP3388514B1 (en) 2023-10-25
CN108699524B (en) 2019-12-10
KR102025417B1 (en) 2019-09-25
US11096967B2 (en) 2021-08-24
AU2017224499B2 (en) 2020-10-08
EP3388514A4 (en) 2018-10-24
RU2727900C2 (en) 2020-07-24
EP3388514A1 (en) 2018-10-17
US20190022144A1 (en) 2019-01-24

Similar Documents

Publication Publication Date Title
SG11201805468RA (en) Pharmaceutical composition for preventing or treating regulatory t cell-mediated diseases
PH12019502661A1 (en) Articles of manufacture and methods for treatment using adoptive cell therapy
MX2020006954A (en) Use of cannabidiol in the treatment of tuberous sclerosis complex.
PH12018500609A1 (en) Method of redirecting t cells to treat hiv infection
MX360702B (en) Method and device for treating or processing containers for substances for medical, pharmaceutical or cosmetic applications.
SG10201806656UA (en) Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer
MX2017007321A (en) Combination therapies.
PH12019550027A1 (en) Uses of pd-1/pd-l1 inhibitors and/or ctla-4 inhibitors with a biologic containing multiple cytokine components to treat cancer
SG10201811128RA (en) Ezh2 inhibitors for treating lymphoma
MY192571A (en) Treatment installation and method for treating workpieces
AR101312A1 (en) COMBINATIONS OF BET INHIBITORS AND INHIBITORS OF TIROSINA QUINASA DE BRUTON
MY176517A (en) Anti-cd38 antibodies for treatment of acute lymphoblastic leukemia
MX2018014577A (en) Combination of anti-cd20 antibody, p13 kinase-delta selective inhibitor, and btk inhibitor to treat b-cell proliferative disorders.
MX2017003099A (en) Absorbent article with an absorbent system having an annular opening.
MX2019001027A (en) Methods, devices, and systems for extraction of oils from plant matter.
MX2020010269A (en) Methods of treating ulcerative colitis.
CO2021011034A2 (en) Methods to treat multiple myeloma
MX2018001849A (en) Methods and compositions using bifidobacterium longum to modulate emotional reactivity and treat or prevent sub-clinical mood disturbances.
PH12017502081B1 (en) Composition, containing quisqualis indica extract, for preventing or treating prostatic hyperplasia
MX2017005522A (en) Novel treatment of cornea using laminin.
MX2015012740A (en) Apparatus, system, and method for processing materials.
MX2017008710A (en) Device and method for the reliable delivery of shaped stopper elements.
SG10201810016XA (en) Methods of treating depression using nmda modulators
MX2019014867A (en) Method for treating a side effect of immunotherapy.
MX2018001666A (en) Method and system for decontaminating food articles having a porous outer surface.